Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...

Trump's pick for HHS secretary who endured confirmation hearings last week—has repeatedly criticized industry ties to the FDA ...

Many or all of the products on this page are from partners who compensate us when you click to or take an action on their website, but this does not influence our evaluations or ratings. Our ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Since the announcement that president-elect Donald Trump would nominate Robert F. Kennedy Jr. (RFK Jr.) as the secretary of the U.S. Department ...

The FDA granted the BLA Priority Review with a Prescription Drug ... of our clinical trial outcomes to support potential approval of any of our product candidates, the FDA review process, review ...

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

Since joining Myeloma Canada's patient advisory council six years ago, he's known three people who have died waiting for a new drug to make its way through the approval process. Often ...

Q: How does the bishop of a diocese go about verifying an apparition, and what does it mean if ecclesial approval is granted? A: The local bishop is the first and main authority in apparition cases, ...

Acalabrutinib received FDA approval for MCL as monotherapy and in combination with bendamustine and rituximab. The ECHO trial showed a 27% reduction in death risk and 34% improvement in ...